Cassava Sciences | PTIE - Interest Expense On Debt


Cassava Sciences reported $100.06M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Abbott USD 297M 2M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
Cara Therapeutics -89.64M 128.67M Dec/2025
Cassava Sciences USD 100.06M 99.31M Sep/2026
Eisai JPY 1.96B 409M Jun/2026
Eli Lilly USD 316M 201.3M Sep/2026
Geron USD 7.21M 61K Sep/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 662M 5M Sep/2026
Roche Holding CHF 304M 7.5M Jun/2025